Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spero TherapeuticsMEX:SPRO 40 Quick Ratio is 6.12 as of Jun. 2026, which is 18% above its 10-year median of 5.18. GuruFocus rates MEX:SPRO with a GF Score™ of 40/100 and a GF Value™ of MXN13.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Spero Therapeutics ranks better than 65.77% on this metric.
Spero Therapeutics (MEX:SPRO) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Spero Therapeutics Quick Ratio Related Terms
Spero Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Spero Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (MEX:SPRO) has a Quick Ratio of 6.12 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Spero Therapeutics and its competitors. This is 18% above median its historical median of 5.18. Over the past decade, Spero Therapeutics' Quick Ratio has ranged from 1.72 to 17.48. According to the industry distribution chart, Spero Therapeutics ranks #483 out of 1411 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Spero Therapeutics' Quick Ratio too high?
Spero Therapeutics' current Quick Ratio of 6.12 is 18% above median its 10-year median of 5.18. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 17.48. The Biotechnology industry median Quick Ratio is 3.59. Spero Therapeutics' value of 6.12 is 70.5% above this industry median. Based on the distribution chart, Spero Therapeutics ranks #483 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spero Therapeutics has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Quick Ratio compare to ?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #483 out of 1411 companies for Quick Ratio. This puts Spero Therapeutics in the upper half of its industry. The industry median Quick Ratio is 3.59. Spero Therapeutics' value of 6.12 is 70.5% above this benchmark. Historically, Spero Therapeutics' own Quick Ratio has ranged from 1.72 to 17.48 over the past decade. While the company's 10-year median is 5.18 vs. the industry median of 3.59, Spero Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current Quick Ratio of 6.12 is 70.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Spero Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current Quick Ratio is 6.12, which is 18% above median its own 10-year median of 5.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (MEX:SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN13.54, compared to a current price of MXN20.74 — trading 53.2% above its estimated fair value. The current Quick Ratio is 6.12, which is 18% above median its 10-year median of 5.18 and 70.5% above the Biotechnology industry median of 3.59. Spero Therapeutics' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Spero Therapeutics (MEX:SPRO), the current Quick Ratio is 6.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for MEX:SPRO:
Quick Ratio: 6.12 (18% above median its 10-year median of 5.18)
GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
Industry Position: 70.5% above the Biotechnology median (#483 of 1411)
No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score
Get the complete analysis for MEX:SPRO
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SPRO has been successfully added to your 
